The Pharmacy Times® Infectious Disease Resource Center is a comprehensive resource for clinical news and expert insights on a group of disorders caused by organisms, such as bacteria, viruses, fungi, or parasites.
March 26th 2024
The test scans whole blood samples from individual human donors for the 5 parasite species that can cause malaria in humans and detects Plasmodium RNA and DNA.
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
Reducing Barriers Associated With Pneumococcal Vaccine Uptake
1.5 Credits / Immunization, Infectious Diseases
View More
Reducing the Incidence and Severity of RSV in Older Adults: Opportunities for Patient Identification and Vaccination Counseling
1.0 Credit / Infectious Diseases, Pulmonology/Respiratory
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Examining the Evidence for Emerging Vaccines to Prevent RSV-Related Complications in Older Adults
2.0 Credits / Infectious Diseases, Respiratory, Immunization
View More
Influenza Prevention in the At-Risk Adult Population and the Pharmacist's Role in an Evolving Influenza Vaccine Landscape
1.25 Credits / Immunization, Infectious Disease
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Monkeypox Treatment and Prevention: Stopping the Latest Outbreak
There is not yet an FDA-approved treatment available for monkeypox, but existing antiviral agents have been found to be effective in vitro and in animal studies.
Read More
Daily Medication Pearl: Famvir (Famciclovir)
June 6th 2022Famvir, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for adults patients who are immunocompetent with herpes labialis (cold sores); treatment of recurrent episodes of genital herpes; and treatment of recurrent episodes, suppressive therapy of recurrent episodes and herpes zoster (shingles).
Read More
Daily Medication Pearl: Symtuza (Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide)
May 25th 2022Symtuza, a 4-drug combination of darunavir (DRV), a HIV-1 protease inhibitor; cobicistat (COBI), a CYP3A inhibitor; and emtricitabine (FTC) and tenofovir alafenamide (TAF), both HIV-1 nucleoside analog reverse transcriptase inhibitors, is indicated as a complete regimen for the treatment of HIV-1 infection in patients who weigh at least 40 kg.
Read More
Mathematical Model Shows How SARS-CoV-2 Variants Could Affect Pandemic Trajectory
November 25th 2021The model could help researchers and public health officials interpret the significance of existing variants and design tailored public health responses for various scenarios based on a variant’s characteristic.
Read More